Requesting your support

Donate to cancer clinical trial research in Canada

Most cancer treatments used today were first proven effective through high-quality cancer clinical trials like those led by the Canadian Cancer Trials Group (CCTG). CCTG is a collaborative network of dedicated researchers, physicians, scientists and statisticians globally recognized for finding treatments that give people with cancer longer, better quality lives. Created in 1980, CCTG is the largest cancer research network in Canada with over 5200 active members and 2100 Canadian investigators. The group has also created an important international network with trials in over 40 countries. CCTG-led trials have resulted in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer.

CCTG is a national program of the Canadian Cancer Society and your donation to clinical trial research supports the work that is done through the group across Canada.

CCTG is the most significant cancer research investment in Canada in terms of direct impact on patients.

However, despite this record of excellence and the countless number of lives saved, CCTG does not have stable funding and has to rely on grants, that are never assured, to continue their work. This means that many necessary trials are on hold or are taking longer to complete.

For example, the Challenge Trial, an international trial expected to improve colon cancer survival rates, is showing great promise but requires funding to test the impact of an exercise treatment on colon cancer survivors. The lack of stable support has slowed trial progress meaning that a potential new treatment has been delayed.

As our understanding of cancer grows, we rely on CCTG to safely conduct clinical trials based on new discoveries. While other organizations support CCTG, it is not enough for the number of trials that are needed. The cure for cancer will come from clinical trials. Your gift will enable CCTG researchers to safely conduct the growing number of trials needed to improve the lives of cancer patients across Canada and the world.

To support any of CCTG's high impact initiatives visit the CCTG Queen's donation page to donate online

The development of a cancer clinical trial - Your support is what makes the difference!

Matching ExCELLirate Canada funding from The Ontario Research Fund

It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".

More >>
 

Successful $30 million Canadian Cancer Society grant renewal for the Canadian Cancer Trials Group

The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group. "CCS is proud to continue to provide core funding for CCTG, and we’re incredibly grateful to our donors who make this support possible," says Dr. Stuart Edmonds, Executive Vice President of Mission, Research & Advocacy at CCS. "With an international reputation for running Canada’s most impactful cancer clinical trials, CCTG’s work benefits not just people with cancer in Canada but around the world." The grant renewal involves a rigorous review process that includes a comprehensive grant submission and site visit with external reviewers looking at all aspects of the Group’s work and impact on clinical trials research. The grant will support CCTG strategic objectives, and the development and conduct of trials.

More >>
 

The CCTG HN11 SELECT trial successfully funded by CIHR

The SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT): The Phase III Randomized Controlled Trial CCTG HN11 has successfully received $3,203,435 in funding from the Canadian Institutes of Health Research in the Fall Research competition.

More >>
 

CIHR funding award announced for rare cancer study

Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition.

Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy.  Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response.

More >>